Axio Biosolutions launches MaxioCel for advanced wound care
- by By Team ABLE - 11 Feb, 2019
Bengaluru-based Axio Biosolutions has launched MaxioCel, a next generation wound care dressing made of chitosan. Dr. V. S. Bedi, Director and Chairman, Vascular and Endovascular Department, Sir Gangaram Hospital, launched MaxioCel at the ‘Endovascular Live 2019’ at Pullman Novotel, New Delhi. In 2018 Axio was claimed to be the first Indian company to get USFDA clearance for its innovative hemostatic dressing - Axiostat. With MaxioCel, the next generation Chitosan-based advance wound care product range, Axio says it is poised to further disrupt the wound care market. The ‘first of its kind’ product is expected to provide comfort and faster healing to patients suffering from chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous leg ulcers, cavity wounds, skin abrasions, donor sites and post-operative surgical wounds, to name some. MaxioCel was launched before an audience of over 300 renowned vascular and endovascular surgeons, interventional radiologists, interventional cardiologists, podiatrists and general surgeons at ‘Endovascular Live 2019’. A paper was presented by Dr. Srujal Shah on experience of using MaxioCel. The presentation mentioned various cases done using MaxioCel range of products – Venous ulcers, diabetic foot ulcers and other complex wounds. Leo Mavely, CEO, Axio Biosolutions, said, “With the latest addition of MaxioCel to our product portfolio, we now have a complete range of innovative products spanning pre-hospital, intra-operative and post-operative clinical needs. India is becoming a world diabetic capital with millions of patients needing advanced wound care products every year. MaxioCel fulfils a large gap in the market with its combined hemostatic, pain management and scar improvement properties. We are proud to bring this product as an Indian innovation in wound care for the world market.”
With MaxioCel, the next generation Chitosan-based advance wound care product range, Axio says it is poised to further disrupt the wound care market.